Targeting the inhibition of Chk1 is a potential strategy for mitigating multidrug resistance (MDR) in NSCLC (Luo and Leverson, 2005; Gadhikar et al., 2013; Itamochi et al., 2014). This evidence concerns the gene CHEK1 and non-small cell lung carcinoma.